CACHE Challenge #1 - Experimental Validation
Preliminary Results

March 21st 2023
The Challenge

• CACHE participants were asked to use their computational methods to predict ligands binding the central cavity of the WDR domain of LRRK2. There is so far no known molecule for this binding site. See details

• After a double-blind peer review where each applicant reviewed 5 applications, 23 participants joined the challenge, representing a diverse array of physics-based and AI computational methods.

• Participants collectively selected 1955 compounds (no more than 100 compounds per participant) that we ordered and received from Enamine.

• All experimental data, the structure of the compounds and their associated computational methods will be publicly released at the end of this Challenge.
Experimental Validation

• Compounds were first screened at 50 µM and 100 µM in a surface plasmon resonance (SPR) binding assay where biotinylated LRRK2-WDR was captured on a streptavidin chip.

• >200 compounds with a binding signal between 50% and 200% of the expected value were cherry picked for dose-response experiment in the same assay

• 73 compounds from 18 participants produced a dose response and measurable $K_D$ below 150 µM and were selected for hit expansion, where participants can select up to 50 follow-up compounds for experimental characterization.

• The hit expansion round will be critical to build confidence in these 73 hit candidates. We expect that progressable hits will produce a clear structure-activity relationship (SAR).
Some of the predicted molecules produced promising data across multiple assays. We hope the hit-expansion round will generate convincing SAR.

**Compound X**

(structure and computational method disclosed at the end of Challenge #1)

- Binds LRRK2-WDR in SPR assay and is specific
- **SPR**
  - Kd=117 µM
  - (Does not bind control anti-target)

- Binds LRRK2-WDR in biolayer interferometry assay
- **BLI**

- Binds untagged LRRK2-WDR in 19F NMR assay
- **19F NMR**

- Is soluble and does not aggregate at 200µM in dynamic light scattering assay
- **Solub.** **Aggreg.**

**Challenge #1**

- 10 µM comp.
- 10 µM comp. + 5 µM prot.
- 10 µM comp. + 10 µM prot.

(Does not bind control anti-target)

Kd=117 µM

Binds LRRK2-WDR in SPR assay and is specific

Binds LRRK2-WDR in biolayer interferometry assay

Binds untagged LRRK2-WDR in 19F NMR assay

Is soluble and does not aggregate at 200µM in dynamic light scattering assay
Some of the predicted molecules produced promising data across multiple assays. We hope the hit-expansion round will generate convincing SAR.

**Compound Y**
(structure and computational method disclosed at the end of Challenge #1)

**Binds LRRK2-WDR in SPR assay and is specific**

**Binds untagged LRRK2-WDR in isothermal titration calorimetry assay**

**Solub.**
(Is soluble and does not aggregate at 200µM in dynamic light scattering assay)

**Kd=44 µM**

**Spr**
(Does not bind control anti-target)

**ITC**

**Solub.**

**Aggreg.**
ACKNOWLEDGEMENTS

CACHE #1 Experimental Platform: Structural Genomics Consortium, University of Toronto

Matthieu Schapira  Pegah Ghiabi
Fengling Li       Elisa Gibson
Suzanne Ackloo    Carla Kharadjian
Sumera Perveen    Almagul Seitova
Irene Chau        Helen Li
Levon Halabelian  Maria Kutera
Serah Kimani      Albina Bolotokova
Shabbir Ahmad     Rachel Harding

FUNDING PARTNERS
The Structural Genomics Consortium is a registered charity (no: 1097737) that receives funds from Bayer AG, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Genome Canada through Ontario Genomics Institute [OGI-196], EU/EFPIA/OICR/McGill/KTH/Diamond Innovative Medicines Initiative 2 Joint Undertaking [EUbOPEN grant 875510], Janssen, Merck KGaA (aka EMD in Canada and US), Pfizer and Takeda.

www.thesgc.org